JP2009536816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536816A5 JP2009536816A5 JP2009503271A JP2009503271A JP2009536816A5 JP 2009536816 A5 JP2009536816 A5 JP 2009536816A5 JP 2009503271 A JP2009503271 A JP 2009503271A JP 2009503271 A JP2009503271 A JP 2009503271A JP 2009536816 A5 JP2009536816 A5 JP 2009536816A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- kit
- albumin
- protein
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 239000002246 antineoplastic agent Substances 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 239000011230 binding agent Substances 0.000 claims 6
- 235000018102 proteins Nutrition 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 5
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 101710027066 ALB Proteins 0.000 claims 4
- 102100001249 ALB Human genes 0.000 claims 4
- 229940050528 albumin Drugs 0.000 claims 4
- 101710042656 BQ2027_MB1231C Proteins 0.000 claims 3
- 229960001592 Paclitaxel Drugs 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 229930003347 taxol Natural products 0.000 claims 3
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 210000000481 Breast Anatomy 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 210000001672 Ovary Anatomy 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 201000001531 bladder carcinoma Diseases 0.000 claims 2
- 201000003963 colon carcinoma Diseases 0.000 claims 2
- 201000001514 prostate carcinoma Diseases 0.000 claims 2
- 201000010174 renal carcinoma Diseases 0.000 claims 2
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 102000015731 Peptide Hormones Human genes 0.000 claims 1
- 108010038988 Peptide Hormones Proteins 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003432 anti-folate Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 claims 1
- 229940045985 antineoplastic drugs Platinum compounds Drugs 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 230000000861 pro-apoptotic Effects 0.000 claims 1
- 235000004252 protein component Nutrition 0.000 claims 1
Claims (18)
- 生物学的サンプル中にＳＰＡＲＣタンパク質又はＳＰＡＲＣ ＲＮＡが存在するかどうかの判定に基づいて投与されることを特徴とする化学療法剤又は他の抗癌剤。
- さらに、Ｈｅｒ２タンパク質又はＨｅｒ２ＲＮＡが存在するかどうかの判定に基づいて投与される、請求項１記載の剤。
- ドセタキセル、パクリタキセル、タキサン、白金化合物、抗葉酸剤、代謝拮抗剤、抗有糸分裂薬、ＤＮＡ損傷剤、アポトーシス促進剤、分化誘導剤、血管新生阻害剤、抗生物質、ホルモン、ペプチド、抗体、及びそれらの組み合わせからなる群より選ばれる、請求項１又は２に記載の剤。
- タンパク質−結合剤の粒子を含む、請求項１−３のいずれか１項に記載の剤。
- タンパク質−結合剤粒子のタンパク質成分がアルブミンを含む、請求項４記載の剤。
- アルブミン−結合パクリタキセルの粒子を含む、請求項１−３のいずれか１項に記載の剤。
- ５０％がナノ粒子の形態である、請求項６記載の剤。
- パクリタキセル用量が約３０ｍｇ／ｍ２から約１０００ｍｇ／ｍ２で、約３週間の投与サイクルで投与される、請求項７記載の剤。
- 乳房、卵巣、頭頸部、結腸、前立腺、膀胱又は腎臓の癌腫用である、請求項１記載の剤。
- 乳房、卵巣、頭頸部、結腸、前立腺、膀胱又は腎臓の癌腫用である、請求項７記載の剤。
- 化学療法剤又は他の抗癌剤に対する哺乳動物の腫瘍の応答を予測するためのキットであって、該腫瘍からのタンパク質の単離手段、ＳＰＡＲＣタンパク質の検出及び定量化手段、コントロールタンパク質、並びに該腫瘍の応答を予測するためのルールを含む、キット。
- 該腫瘍のＨｅｒ２状態を判定する手段をさらに含む、請求項１１記載のキット。
- 化学療法剤がアルブミン−結合剤の粒子を含み、５０％を超える化学療法剤がナノ粒子の形態である、請求項１１記載のキット。
- アルブミン−結合剤がアルブミン−結合パクリタキセルである、請求項１３記載のキット。
- 化学療法剤又は他の抗癌剤に対する哺乳動物の腫瘍の応答を予測するためのキットであって、該腫瘍からのＲＮＡの単離手段、ＳＰＡＲＣ ＲＮＡの検出及び定量化手段、コントロールＲＮＡ、並びに腫瘍中のＳＰＡＲＣ ＲＮＡレベルに基づいて該腫瘍の応答を予測するためのルールを含む、キット。
- 該腫瘍のＨｅｒ２状態を判定する手段をさらに含む、請求項１５記載のキット。
- 化学療法剤がアルブミン−結合剤の粒子を含み、５０％を超える化学療法剤がナノ粒子の形態である、請求項１５記載のキット。
- アルブミン−結合剤がアルブミン−結合パクリタキセルである、請求項１７記載のキット。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78820806P | 2006-03-31 | 2006-03-31 | |
| US60/788,208 | 2006-03-31 | ||
| PCT/US2007/065486 WO2008060651A2 (en) | 2006-03-31 | 2007-03-29 | Sparc and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009536816A JP2009536816A (ja) | 2009-10-22 |
| JP2009536816A5 true JP2009536816A5 (ja) | 2010-05-20 |
| JP5756596B2 JP5756596B2 (ja) | 2015-07-29 |
Family
ID=39402301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503271A Expired - Fee Related JP5756596B2 (ja) | 2006-03-31 | 2007-03-29 | Ｓｐａｒｃ及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8415304B2 (ja) |
| EP (1) | EP2010919B1 (ja) |
| JP (1) | JP5756596B2 (ja) |
| CN (1) | CN101454673B (ja) |
| AU (2) | AU2006249235B2 (ja) |
| BR (1) | BRPI0710111A2 (ja) |
| CA (1) | CA2648118C (ja) |
| ES (1) | ES2687076T3 (ja) |
| WO (1) | WO2008060651A2 (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| NZ623273A (en) | 2008-12-05 | 2015-09-25 | Abraxis Bioscience Llc | Sparc binding scfvs |
| CA2960887C (en) | 2009-05-28 | 2018-09-04 | Abraxis Bioscience, Llc | Use of 2 anti-sparc antibodies to predict response to chemotherapy |
| AU2010295324B2 (en) * | 2009-09-18 | 2015-04-30 | Abraxis Bioscience, Llc | Use of the SPARC microenvironment signature in the treatment of cancer |
| CA2785469C (en) * | 2009-12-22 | 2019-07-23 | Expression Pathology, Inc. | Secreted protein acidic and rich in cysteine (sparc) protein srm/mrm assay |
| CA2792667A1 (en) * | 2010-03-11 | 2011-09-15 | Abraxis Bioscience, Llc | Sparc angiogenic domain and methods of use |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
| NZ604029A (en) * | 2010-06-02 | 2015-07-31 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| KR20130086546A (ko) * | 2010-06-03 | 2013-08-02 | 아브락시스 바이오사이언스, 엘엘씨 | 암 치료에 있어 ｓｐａｒｃ 미세환경 시그니처의 용도 |
| AU2011261270A1 (en) * | 2010-06-03 | 2012-12-13 | Abraxis Bioscience, Llc | Peripheral blood SPARC antibodies and uses thereof |
| RU2016103126A (ru) * | 2010-06-07 | 2018-11-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы комбинированной терапии для лечения пролиферативных заболеваний |
| WO2012051220A1 (en) * | 2010-10-11 | 2012-04-19 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
| KR20200051841A (ko) | 2011-04-28 | 2020-05-13 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| JP6042527B2 (ja) | 2012-04-04 | 2016-12-14 | ハロザイム インコーポレイテッド | 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療 |
| US20170000899A1 (en) * | 2013-11-26 | 2017-01-05 | The Brigham And Women's Hospital, Inc. | Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| GB201721308D0 (en) * | 2017-12-19 | 2018-01-31 | Nordic Bioscience As | SPARC assay |
| US20190356621A1 (en) * | 2018-05-17 | 2019-11-21 | Koninklijke Philips N.V. | Adapting silence periods for digital messaging |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| IL108497A0 (en) | 1993-02-01 | 1994-05-30 | Seq Ltd | Methods and apparatus for dna sequencing |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5738852A (en) | 1993-04-20 | 1998-04-14 | Solis Therapeutics, Inc. | Methods of enhancing antigen-specific T cell responses |
| US5945515A (en) * | 1995-07-31 | 1999-08-31 | Chomczynski; Piotr | Product and process for isolating DNA, RNA and proteins |
| HUP9900017A3 (en) | 1995-09-21 | 2001-08-28 | Andaris Ltd Ruddington | Transcytosis vehicles and enhancers for drug delivery |
| AU5333298A (en) | 1996-12-27 | 1998-07-31 | Instituto De Investigaciones Bioquimicas Fundacion Campomar | Compositions and methods for tumour therapy |
| US6187307B1 (en) | 1997-01-31 | 2001-02-13 | Research Corporation Technologies, Inc. | Cancer immunotherapy with semi-allogeneic cells |
| DE19740571C1 (de) | 1997-09-15 | 1999-03-18 | Gsf Forschungszentrum Umwelt | Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität |
| WO2000006152A1 (en) | 1998-07-30 | 2000-02-10 | Novopharm Biotech, Inc. | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
| US6316193B1 (en) | 1998-10-06 | 2001-11-13 | Origene Technologies, Inc. | Rapid-screen cDNA library panels |
| US20040018188A9 (en) * | 1999-01-20 | 2004-01-29 | Incyte Genomics, Inc. | Sparc-related proteins |
| US20020015950A1 (en) | 1999-07-07 | 2002-02-07 | Karen Anne Jones | Atherosclerosis-associated genes |
| US6387664B1 (en) | 1999-02-26 | 2002-05-14 | Secretary Of Agency Of Industrial Science And Technology | Sparc fusion protein and method for producing the same |
| EP1182929A4 (en) | 1999-05-28 | 2003-04-16 | Univ Virginia | TOXIC GENE THERAPY BASED ON OSTEONECTIN FOR TREATING CALCIFIED TUMORS AND TISSUES |
| WO2001020989A1 (en) | 1999-09-22 | 2001-03-29 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| BR0014491A (pt) | 1999-10-04 | 2004-03-09 | Vion Pharmaceuticals Inc | Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão |
| US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
| JP2003530893A (ja) | 2000-04-25 | 2003-10-21 | ディーエヌエー サイエンシーズ インコーポレーテッド | ポリメラーゼのプルーフリーディング活性によるヌクレオチド配列変異の検出 |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| WO2002002771A2 (en) | 2000-07-05 | 2002-01-10 | Eli Lilly And Company | Human sparc-homologous (hsparc-h1) gene and methods and uses thereof |
| WO2004005883A2 (en) | 2002-07-02 | 2004-01-15 | The Johns Hopkins University | Secreted and cytoplasmic tumor endothelial markers |
| EP1572934A4 (en) | 2002-02-21 | 2007-12-19 | Wyeth Corp | FOLLISTATIN DOMAIN CONTAINING PROTEINS |
| US20050272052A1 (en) | 2002-04-09 | 2005-12-08 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
| EP2561887B8 (en) | 2003-01-14 | 2016-12-21 | Dana-Farber Cancer Institute, Inc. | Cancer therapy sensitizer |
| EP2060918A3 (en) * | 2003-04-01 | 2009-08-26 | The Johns Hopkins University | Breast endothelial cell expression patterns |
| JP2007507222A (ja) * | 2003-05-28 | 2007-03-29 | ゲノミック ヘルス， インコーポレイテッド | 化学療法に対する応答を予測するための遺伝子発現マーカー |
| FR2857675B1 (fr) * | 2003-07-18 | 2006-01-13 | Staubli Sa Ets | Cadre lisses et metier a tisser pourvu d'au moins un tel cadre |
| US7700280B2 (en) | 2003-12-31 | 2010-04-20 | The Penn State Research Foundation | Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer |
| AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| EP1755653B1 (en) * | 2004-05-14 | 2014-12-31 | Abraxis BioScience, LLC | Treatment methods utilizing albumin-binding proteins as targets |
| US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
-
2006
- 2006-12-04 AU AU2006249235A patent/AU2006249235B2/en not_active Ceased
-
2007
- 2007-03-29 CA CA2648118A patent/CA2648118C/en active Active
- 2007-03-29 WO PCT/US2007/065486 patent/WO2008060651A2/en active Application Filing
- 2007-03-29 CN CN200780019544.0A patent/CN101454673B/zh not_active Expired - Fee Related
- 2007-03-29 US US12/295,068 patent/US8415304B2/en active Active
- 2007-03-29 BR BRPI0710111-2A patent/BRPI0710111A2/pt not_active Application Discontinuation
- 2007-03-29 ES ES07868202.8T patent/ES2687076T3/es active Active
- 2007-03-29 JP JP2009503271A patent/JP5756596B2/ja not_active Expired - Fee Related
- 2007-03-29 AU AU2007319763A patent/AU2007319763B2/en not_active Ceased
- 2007-03-29 EP EP07868202.8A patent/EP2010919B1/en active Active
-
2013
- 2013-03-08 US US13/791,009 patent/US8946169B2/en active Active
-
2015
- 2015-01-30 US US14/610,099 patent/US9671406B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536816A5 (ja) | ||
| Sun et al. | Multifunctional poly (D, L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer | |
| Cui et al. | The CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis | |
| Singh et al. | TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy | |
| Kanwar et al. | Survivin signaling in clinical oncology: a multifaceted dragon | |
| Lin et al. | CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression | |
| Chang et al. | Shape engineering boosts magnetic mesoporous silica nanoparticle-based isolation and detection of circulating tumor cells | |
| Thomas et al. | Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy | |
| Fan et al. | Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration | |
| Pokorski et al. | Cell targeting with hybrid Qβ virus‐like particles displaying epidermal growth factor | |
| Wang et al. | Microarray based screening of peptide nano probes for HER2 positive tumor | |
| Wang et al. | Rapid screening of peptide probes through in situ single-bead sequencing microarray | |
| Lin et al. | Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway | |
| JP2012019790A5 (ja) | ||
| CA2648118A1 (en) | Methods using sparc for predicting the response of a tumour to chemotherapy agents | |
| Li et al. | Increased CD34+ CD38− CD123+ cells in myelodysplastic syndrome displaying malignant features similar to those in AML | |
| Jeevanandam et al. | Advancing aptamers as molecular probes for cancer theranostic applications—the role of molecular dynamics simulation | |
| JP2011121944A5 (ja) | ||
| JP2015505818A5 (ja) | ||
| Song et al. | Advances in aptamer-based nuclear imaging | |
| Yoo et al. | Highly dense, optically inactive silica microbeads for the isolation and identification of circulating tumor cells | |
| WO2013049830A2 (en) | Tip-1 and grp-78 binding peptides and method of identifying peptide receptors | |
| JP2014166186A5 (ja) | ||
| HRP20230878T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raznih karcinoma (seq id 25 - mrax5-003) | |
| Gupta et al. | In silico analysis of differential gene expressions in biliary stricture and hepatic carcinoma |